HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback